View : 60 Download: 0

Consensus update for systemic treatment of atopic dermatitis

Title
Consensus update for systemic treatment of atopic dermatitis
Authors
Lee J.H.Kim J.E.Park G.-H.Bae J.M.Byun J.Y.Shin M.K.Han T.Y.Hong S.P.Jang Y.H.Kim H.O.Na C.H.Lew B.-L.Ahn J.Park C.O.Seo Y.-J.Lee Y.W.Son S.W.Choi E.H.Park Y.L.Roh J.Y.
Ewha Authors
변지연
SCOPUS Author ID
변지연scopus
Issue Date
2021
Journal Title
Annals of Dermatology
ISSN
1013-9087JCR Link
Citation
Annals of Dermatology vol. 33, no. 6, pp. 497 - 514
Keywords
Atopic dermatitisConsensusRepublic of KoreaSystemic treatmentTherapeutics
Publisher
Korean Dermatological Association
Indexed
SCIE; SCOPUS; KCI WOS scopus
Document Type
Review
Abstract
Background: In 2015, the Korean Atopic Dermatitis Association (KADA) working group published consensus guidelines for treating atopic dermatitis (AD). Objective: We aimed to provide updated consensus recommendations for systemic treatment of AD in South Korea based on recent evidence and experience. Methods: We compiled a database of references from relevant systematic reviews and guidelines on the systemic management of AD. Evidence for each statement was graded and classified based on thestrength of the recommendation. Forty-two council members from the KADA participated in three rounds of voting to establish a consensus on expert recommendations. Results: We do not recommend long-term treatment with systemic steroids forpatients with moderate-to-severe AD due to the risk of adverse effects. We recommend treatment with cyclosporine or dupilumab and selective treatment with methotrexate or azathioprine for patients with moderate-to-severe AD. We suggest treatment with antihistamines as an option for alleviating clinical symptoms of AD. We recommend selective treatment with narrowband ultraviolet B for patients with chronic moderate-to-severe AD. We do not recommend treatment with oral antibiotics for patients with moderate-to-severe AD but who have no signs of infection. We did not reach a consensus on recommendations for treatment with allergen-specific immunotherapy, probiotics, evening primrose oil, orvitamin D for patients with moderate-to-severe AD. We also recommend educational interventions and counselling for patients with AD and caregivers to improve the treatment success rate. Conclusion: We look forward to implementing a new and updated consensus of systemic therapy in controlling patients with moderate-to-severe AD. Copyright © The Korean Dermatological Association and The Korean Society for Investigative Dermatology
DOI
10.5021/AD.2021.33.6.497
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE